Loading
A phase 2 trial of Gemcitabine in cervical cancer, run by Grit Biotechnology, now recruiting.
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06241781 by Grit Biotechnology, with 83 participants planned, started 2024-04-02 and due to reach its primary completion in 2027-01-31. Interventions recorded: GT101 injection and Gemcitabine injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Grit Bio and the tag pipeline.
Shares Grit Bio and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/